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Objective: to determine whether the laboratory hematic curve must be the single predictor
of  postoperative blood transfusion in total hip arthroplasty.
Methods: the laboratory blood samples of 78 consecutive patients undergoing total hip
arthroplasty  was analyzed during ﬁve distinct moments: one preoperative and four postop-
erative.  There was a count of hemoglobin, hematocrit and platelets of the patients samples.
Other  catalogued variables ascertain possible risk factors related to transfusional practice.
They  characterized the anthropometric, behavioral and co morbidities data in this popula-
tion.  The study subjects were divided and categorized into two groups: those who received
blood  transfusion during or after surgery (Group 1, G1), and those who did not accomplish
blood  transfusion (Group 2, G2). Transfusion rules were lead by guidelines of American
Academy  of Anesthesiology and the British Society of Hematology.
Results:  a total of 27 (34.6%) patients received blood transfusions. The curves of hemoglobin,
hematocrit  and platelet transfusions between G1 and G2 were similar (p > 0.05). None of the
analyzed risk factors modiﬁed the rate of transfusion rate in their analysis with p value > 0.05,
except the race. The sum of clinical co morbidities associated with patients in G1 was  a
median of 3 (95% CI 2.29–3.40), while in G2 the median was 2 (95% CI 1.90–2.61) with p = 0.09.
Conclusion:  the curve in red blood cells has limited reliability when used as sole parameter.
The  existence of tolerant patients hematimetric curve variations assumes that their assess-
ments of clinical, functional evaluation and co-morbidities are parameters that shouldinﬂuence  the decision to transfusion red blood cells.
©  2013 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda.  
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Transfusão  sanguínea  em  artroplastia  de  quadril:  a  curva  laboratorial
hemática  deve  ser  o  único  preditor  da  necessidade  de  transfusão?
Palavras-chave:
Artroplastia de quadril
Transfusão  sanguínea
Hemoglobina
r  e  s  u  m  o
Objetivo: veriﬁcar se a curva laboratorial hemática deve ser o único preditor de transfusão
sanguínea pós-operatória em artroplastia total de quadril (ATQ).
Métodos:  amostras laboratoriais sanguíneas de 78 pacientes consecutivos submetidos à
ATQ foram analisadas em cinco em períodos distintos (um pré-operatório e quatro pós-
-operatórios). Veriﬁcou-se a contagem de hemoglobina, hematócrito e plaquetas desses
pacientes. Foram analisadas características antropométricas e comportamentais e comor-
bidades referentes à amostra, para veriﬁcac¸ão  de fatores de risco associados à prática
transfusional. Os indivíduos do estudo foram divididos em dois grupos: aqueles que rece-
beram transfusão sanguínea foram alocados no Grupo 1 (G1) e os que não a receberam,
no Grupo 2 (G2). As condutas transfusionais respaldaram-se dos critérios da Academia
Americana de Anestesiologia e da Sociedade Britânica de Hematologia.
Resultados:  receberam transfusão de hemoderivados 27 (34,6%) pacientes. As análises das
curvas de hemoglobina, hematócrito e plaquetas entre o G1 e o G2 nas cinco visitas distintas
foram similares (p > 0,05). Todos os fatores de risco analisados, com excec¸ão  da etnia, não
apresentaram repercussões nos índice de transfusão em suas análises com valor p > 0,05. A
soma das comorbidades clínicas associadas aos pacientes no G1 foi mediana de 3 (IC 95%
2,29–3,40), enquanto no G2 a mediana foi 2 (IC 95% 1,90–2,61) com valor p = 0,09.
Conclusão:  a curva hemática apresenta conﬁabilidade limitada quando usada como
parâmetro exclusivo e absoluto. A existência de pacientes tolerantes às variac¸ões  da curva
hematimétrica pressupõe que as suas avaliac¸ões  de caráter clínico, funcional e de comor-
bidades sejam parâmetros que devam inﬂuenciar na decisão do uso de hemoderivados.
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
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he indication for blood transfusion in prosthetic orthopedic
rocedures – especially hip arthroplasty – generates disagree-
ent  among medical professionals as the management of
ost-surgical  anemia.1–4 The standardization of transfusional
rocedures in the post-operative management with labora-
ory  thresholds was  initially done in 1942,5 because of the fear
f  complications such as fatigue and inability to recover and
ehabilitate  the patient, together with the high costs and with
he  morbidity and long hospital stays. Further understand-
ng  of human physiology brought greater doubt about the use
f  preset laboratory thresholds for transfusion. Because of
he  risk of bleeding during and after surgery, and of drainage
nd  secretion of the surgical wound, its imposition as routine
ractice  was  countered by the risks related to the conse-
uences of its use. We report an association of this practice
ith  highest rates of surgical site infection,4,6 and increase of
ost-operative pneumonia index and mortality in the short
erm,  and vascular events, besides autoimmune reactions,
ystemic inﬂammatory response syndrome, and transmission
f  contagious diseases.6–8
Numerous guidelines depict the local experience of spe-
iﬁc  centers, or demonstrate the scenario of medical groups’
rocedures in several countries,9–11 but there is no support
12r  speciﬁc worldwide standardization for these conducts.
rominent studies warn about the risk factors associated with
lood  transfusions, being adamant in deﬁning optional preop-
rative  methods for reducing the costs and morbidities relatedEditora Ltda. 
to the use of allogeneic blood products. The use before, during
and  after the surgical procedures of substances such as fer-
rous  sulphate, erythropoietin, trenexamic acid, recombinant
factor  VII and ﬁbrin glue, and the promotion of protocols of
autotransfusion, hemodilution and rescue of red blood cells,8
are the main approaches, although not without risks,8 to solve
this  issue.4,6,13–17
The gaps related to the conducts regarding the use of blood
products  led us to deﬁne the overall functioning of the post-
operatory  laboratory hematic curve of patients undergoing
primary total hip arthroplasty (THA) in this orthopedic refer-
ral  service. The objective was  to understand the real need
for  blood transfusions based on their laboratory results. In
this  study, possible factors that could inﬂuence the transfu-
sion  procedures were examined, to explain why  some patients
presented  clinical and laboratory recovery without the use of
blood  transfusion, based on absolute numbers. This analysis
questions  and alerts about necessary precautions of routine
blood  transfusion.
Materials  and  methods
From January 2011 to June 2012 those patients undergoing THA
in the Santa Casa de Porto Alegre (HSCPOA) Hospital Com-
plex  were  enrolled in this prospective study. Seventy-eight
Este é um artigo Open Access sob a licença de CC BY-NC-NDparticipants were randomized and provided written informed
consent.  This study was  approved by the HSCPOA institutional
ethics  and research board. Patients with any hematopoietic
disorder, hemoglobin levels below 10 g/dL, active contagious
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Table 1 – Risk factors among transfused (G1) and not transfused (G2) patients (comparison between means of parametric
continuous variables and median of the nonparametric variable).
Variable (means ± standard deviation) Transfused (G1) Not transfused (G2) Total p
Agea 56.44 ± 15.07 59.58 ± 11.82 58.5 ± 13.02 0.31
Weighta 71.68 ± 17.53 73.18 ± 13.72 72.6 ± 15.05 0.67
BMIa 25.97 ± 5.58 27.59 ± 4.57 27.09 ± 4.97 0.17
MBPa 93.11 98.34 96.54 0.11
Preoperatory hemoglobina 13.51 ± 1.55 13.60 ± 1.36 13.59 ± 1.42 0.91
Trans-operatory bleedinga 540 ± 272.11 414.84 ± 142.37 458.98 ± 205.08 0.019
Post-operatory bleedinga 262.42 ± 219. 52 218.66 ± 175.35 238.56 ± 205.27 0.09
Sum of comorbitiesb (median and CI 95%) 4 (IC 95% 2.29–3.40) 2 (IC 95% 1.9–2.61) 0.09
CI, conﬁdence interval.
a Student t-test.
b Mann–Whitney U-test.
or infectious chronic liver disease, and with malignant tumor
were  excluded from the study.
Patients rigidly followed a protocol for collecting data
through serial visits. The ﬁrst visit (V1) occurred preoper-
atively (from seven to three days before surgery); in this
stage,  ﬁrst hematimetric laboratory tests and demographics
and  physical data of the participants (gender, age, ethnic-
ity,  weight, height, body weight index [BMI], comorbidities,
alcoholism, smoking, and vital signs) were collected; in the
second  visit (V2), which occurred on the ﬁrst post-operative
day (6–12 h after surgery), the second laboratory hematimet-
ric  sample and data regarding surgery were collected, and the
drainage  of the suction drain was  calculated; the third visit
(V3)  occurred on the second post-operative day (24–48 h after
surgery),  with the same procedures of V2; the fourth (V4) and
the  ﬁfth (V5) visits occurred in the ﬁrst (between 4 and 7 days)
and  third weeks (14–17 days) post-operatively, respectively,
and  were  characterized by laboratory collection and data from
late  post-operative period. In the laboratory evaluation, we
analyzed  the red series hemocytometry (hemoglobin, hemat-
ocrit  and platelets). The sample collections were done during
the  hospital stay (V2–V3–V4) and in the outpatient clinic (V1
and  V5).
All  patients were  operated on by the same surgical team,
consisting of two surgeons and two anesthetists. The surgi-
cal  routine consisted of calculating the intraoperative bleeding
(through  the suction volume of the drains and by weighing the
pads)  and of a general description of the prosthetic procedure.
The  anesthetic routine was  similar in all patients: spinal anes-
thesia  followed by sedation. The posterior surgical technique
for  access for all cases of THA was  chosen. During the clo-
sure  of the surgical plans, all patients received closed suction
drains,  which were  maintained for 48 h. The mean operative
time  was  98.3 ± 4.2 min  (range: 80–120 min). Post-operatively,
all patients used prophylactic unfractionated heparin (5000
units  12/12 h) for a minimum of seven days and vacuum
suction drain for two days. No patient received steroid or
anti-inﬂammatory medication. Analgesic drugs were based on
opioids and non-narcotic pirazolonic derivatives (dipyrone).
The  procedures of intraoperative and post-operative trans-
fusion  of the anesthetic/surgical team were obeyed, and
criteria  based on guidelines were used in their conduct.18,19
Blood products were used during surgery when there was
signiﬁcant bleeding that would interfere with the patient’shemodynamic status. The anesthetist was solely responsible
for  the use/degree of the blood product. Post-operatively, of
necessity  the healthy patients received blood products with
Hb  < 7 g/dL, whereas those with cerebrovascular disease, coro-
nary  artery disease, peripheral vascular disease and chronic
pulmonary vascular disease received blood transfusions with
Hb  < 8 g/dL.
According to transfusion criteria, we allocate the patients
into  two groups: Group 1 (G1) – patients who received blood
transfusion; and Group 2 (G2) – patients who did not receive
blood  products. In this study population, the participants
had a mean age of 58.5 ± 13 (G1 = 56.4 and G2 = 15 ± 59.5 ± 11.8
(p  = 0.31). Weight and BMI of G1 and G2, respectively, were
71.6  ± 17.5/25.9 ± 5.5 and 73.1 ± 13.7/27.5 ± 4.5 (p > 0.05). Preop-
eratively,  the mean arterial pressure (MAP) was  96.54 mmHg
(p  > 0.05) for G1 (93.11 mmHg) and G2 (98.34 mmHg) groups.
Preoperative hemoglobin for G1 and G2 was 13.5 ± 1.5 and
13.6  ± 1.3 (p = 0.91), respectively (Table 1).
Patients  were  sorted and analyzed by SPSS 17.0 soft-
ware  (Chicago, IL, USA). For continuous variables, descriptive
statistics demonstrated performance characteristics (cen-
tral  tendency and dispersion). By the adherence test of
Kolmogorov–Smirnov (K–S), with the Lilliefors correction of
normality,  the normality of data was tested. Analysis of
variance  (ANOVA) for hematological curves was  adopted.
Additional tests (post hoc) were  conducted to evaluate spe-
ciﬁc  differences between means, by pairs. In the analysis of
risk  factors, the discrete variables were  assessed by Yates
chi-square test, whereas for parametric and nonparametric
continuous variables the Student t test and Mann–Whitney,
respectively, were  used. In all interpretations, the level of sig-
niﬁcance  was set at p < 0.05.
Results
Twenty-seven (34.6%) patients received blood transfusions:
19  (55.6%) during surgery and 12 (44.4%) post-operatively.
The average intraoperative blood loss was 458.9 ± 205 mL
(G1  = 540 ± 272 mL  and G2 = 414.8 ± 142.3 mL  [p = 0.019]).
Mean post-operative bleeding was  238, 56 ± 205.27 mL
(G1  = 262.4 ± 219.5 mL  and G2 = 218.6 ± 175.3 mL  [p = 0.09]).
The  curves of hemoglobin, hematocrit and platelets among
transfused (G1) and not transfused (G2) patients displayed
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Table 2 – Hemoglobin, hematocrit and platelet values among transfused (G1) and not transfused (G2) patients in ﬁve
visits (V1–V5).
Hb (g/dL) Hb (V1) (g/dL) Hb (V2) (g/dL) Hb (V3) (g/dL) Hb (V4) (g/dL) Hb (V5) (g/dL) pa
G1 13.57 ± 1.55 11.44 ± 1.73 9.6 ± 1.64 10.8 ± 1.53 12.55 ± 1.58 >0.05
G2 13.6 ± 1.36 11.45 ± 1.76 10.2 ± 1.52 11.1 ± 1.45 12.48 ± 1.29
Ht (%) Ht (V1) (%) Ht (V2) (%) Ht (V3) (%) Ht (V4) (%) Ht (V5) (%)
G1  38.81 ± 4.48 32.85 ± 5.04 27.88 ± 4.69 31.78 ± 4.62 36.79 ± 4.4 >0.05
G2 40.08 ± 4.05 33.79 ± 4.75 30.04 ± 4.58 33.03 ± 4.07 36.93 ± 3.65
Platelets (mm3) Platelets (V1) (mm3) Platelets (V2) (mm3) Platelets (V3) (mm3) Platelets (V4) (mm3) Platelets (V5) (mm3)
G1 (mm3) 250.69 ± 43.23 231.92 ± 77.11 270.5 ± 77.4 466.75 ± 114.9 283.78 ± 67.99 >0.05
G2 (mm3) 245.22 ± 66.39 215.14 ± 77.11 286.93 ± 83.73 476.4 ± 170.48 266.97 ± 105.89
a Considering the curve analysis by ANOVA and at each respective visit (V1–V5) in the post hoc test.
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(Table 1). Except for ethnicity, nonparametric variables such
as  smoking, alcoholism, cemented or not cemented implant,
hypertension and diabetes had an impact on rates of transfu-
sion  in their analysis, with p > 0.05 (Tables 1 and 3). The sum
of  comorbidities associated with patients in G1 had a median
of  3 (95% CI 2.29–3.40), while in G2 the median was  2 (95% CI
1.90–2.61)  (p = 0.09) (Table 1).
Discussion
The standardization of transfusional conducts is still a chal-
lenging  topic. In the ﬁrst studies, dating from the 1940s,5 the
hemoglobin  value adopted for post-surgery control of ane-
mia  was 10 g/dL. This limit was changed in the early 1990s,
with  the expansion of knowledge about the behavior of acute
(traumatic  and surgical) shock and with detailed studies of
the  use of blood products in patients with severe disease.
The  guidelines then began to orient the new transfusional
conducts,18,19 even in speciﬁc areas such as orthopedia.20 The
hemoglobin thresholds were modiﬁed, from 10 g/dL to 7 g/dL
in  healthy patients and to 8 g/dL in patients with a comorbidity
(age  > 65 years, with respiratory disease and occlusive vascu-
lar  disease).4 From these numbers, another argument, namely,
the  possible subjective criteria that could guide the conduct of
every  professional, regardless of laboratory numerical anal-
ysis,  emerged. This can be seen in studies that generally
collected and analyzed national or international multicentric
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Table 3 – Risk factors among transfused (G1) and not transfused (G2) patients (association between discrete qualitative
variables).
Discrete variables Transfused (G1) Not transfused (G2) Total p
Gendera
Male 17 (21.8%) 26 (33.3%) 43 (55.1%) 0.31
Female 10 (12.8%) 25 (32.1%) 35 (44.9%)
Etnicitya
Caucasian 26 (33.3%) 40 (51.3%) 66 (84.6%) 0.03
Black 1 (1.3%) 11 (14.1%) 12 (15.4%)
Tabagisma
Yes 9 (11.5%) 11 (14.1%) 20 (25.6%) 0.25
Not 18 (23.1%) 40 (51.3%) 58  (74.4%)
Alcoholisma
Yes 14 (17.9%) 19 (24.4%) 33 (42.3%) 0.21
Not 13 (16.7%) 32 (41.0%) 45 (57.7%)
Hypertensiona
Yes 13 (16.7%) 23 (29.5%) 36  (46.2%) 0.79
Not  14 (17.9%) 28 (35.9%) 42 (53.8%)
Type of prosthesisa
Cemented 19 (24.4%) 30 (38.5%) 49 (62.8%) 0.31
Not cemented 8 (10.3%) 21 (26.9%) 29 (37.2%)a Yates chi-squared test.
conducts.2,12,20 Those studies portrayed divergent attitudes
toward transfusion measures among different centers,2,21 and
even  among medical professionals of different subspecialties.
Young et al.1 demonstrated that surgeons have a more  aggres-
sive  transfusion conduct, especially when hemoglobin values
ranged  from 7 g/dL to 10 g/dL. In this study, from a total of 44
patients  who had hemoglobin levels between 10 and 7 g/dL,
27  were  not transfused with blood products. This implies that
perhaps  more  restrict transfusional measures are adopted in
the post-surgical area. We believe that objective criteria may
lose  its power to inﬂuence the post-operative period, by subdi-
viding  the responsibility for the recovery of the hematimetric
curve with the clinic of the patients and their potential risk
factors.  However, this situation does not occur during intra-
operative  transfusions, which, although reliably quantify the
necessity  of blood replacement,18,19 represented 55% of trans-
fusions  in this study. This aggressive transfusional attitude
is  explained by the situational and dynamic medical conduct
determined by intraoperative acute events. The main reasons
for  transfusion selected by the anesthetists were: transient
hypotension unresponsive to crystalloids and trans-operatory
disturbances of cardiac and respiratory rhythm caused by
transitory  shock. It is important to consider that the main
guidelines are categorical in their conclusions. They deﬁne
that  the absolute numbers are not the only decisive factors
exclusively for taking perioperative decisions,18,19 despite the
tendency  of most health professionals, toward keeping their
conduct  based solely on laboratory values.22
It is estimated that in the area of hip replacement surgery
the  rates of blood transfusions can vary between 33 and 74% of
patients.4,8 These numbers reinforce the ﬁndings of this study,
in  which 34.6% of patients received blood products, despite
the  option for the more  restrictive transfusion behaviors. This
demonstrates that the need for improvement of these indices
remains  a challenge that is awaiting for better solutions.In  order to ascertain the possible variables that inﬂuence
the  transfusion rates, speciﬁc studies of blood transfusion
in  elective orthopedic procedures preferred to stick to the
main  transfusion criteria, risk factors and use of optional
methods,4,6,12,14–16 failing to emphasize the importance of the
behavior of the laboratory curve. In this study, we  demon-
strated  an objective approach to the behavior of the curves of
hemoglobin,  hematocrit and platelets. As a result, we  found
behavioral  similarity between the two analyzed groups, and
this  ﬁnding answered the question of the study: patients
generally have similar recovery speed of the hematimetric
values, regardless of blood transfusion. From this premise,
some  assumptions are evident. There is a signiﬁcant number
of  individuals tolerant to surgical blood loss below the pre-
determined thresholds and these people present a satisfactory
functional recovery without using blood products.22
In order to ascertain the possible variables inﬂuencing the
transfusion rates, speciﬁc studies of blood transfusion in elec-
tive  orthopedic procedures has been either complied with
major  transfusion criteria, risk factors and use of optional
methods,4,6,12,14–16 and did not emphasize the importance
of the behavior of the laboratory curve. In this study, we
demonstrated an objective approach to the behavior of the
curves  of hemoglobin, hematocrit and platelets. As a result,
we  observed behavioral similarity between the two analyzed
groups,  and this answered the question of the study: patients
generally  have similar rate of recovery from hematimetric val-
ues, regardless of blood transfusion. From this premise, some
assumptions  are evident. There is a signiﬁcant number of indi-
viduals tolerant to surgical blood loss below predetermined
thresholds and that present a satisfactory functional recovery
without  using blood products.22In elective orthopedic surgeries, there is a need for a min-
imum  level of preoperative Hb, with the variant value of
11  g/dL.8 However, for the post-operative control there are no
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1. Young SW, Marsh DJ, Akhavani MA, Walker CG, Skinner JA.r e v b r a s o r t o p
imiting requirements. Carson et al.23,24 found that there was
o  beneﬁt in functional recovery with maintaining Hb levels
bove  10 g/dL, even in symptomatic patients (besides vascular
isease),  compared with those who maintained the basal level
elow  8 g/dL after hip orthopedic surgeries.23 Hebert et al.25
ound that early mortality has not changed in 838 critically
ll  patients who received aggressive transfusion (Hb < 10 g/dL),
ompared  with those who had more  restrict transfusions
Hb < 7 g/dL). Viele et al.26 analyzed patients (all of them
ehovah’s Witnesses) who  tolerated Hb levels below 8 g/dL,26
ith adequate recovery and presented preliminary demands
nly  when the levels reached less than 5 g/dL (in association
ith  increased risk of morbidity and mortality). The indices
f  hematocrit follow a tolerance threshold for transfusion
etween values of 18–25%,18 and can reach 15–20% without
yocardial damage caused by lactic acid production. Car-
iac  failure occurs when the thresholds are close to 10%.3,18
egarding platelets, preoperative minimum indices are rele-
ant  when they are below 50,000 mm3, a circumstance remote
rom  most patients undergoing elective THA – which explains
he  null rate speciﬁc for platelet transfusions.
The behavior of hemoglobin and hematocrit curves fol-
owed  a parabolic path with normal distribution of data and a
ownward peak was  observed during the visit 3; regardless of
ransfusion,  the peak had returned to the baseline threshold
t  visit 5. The graphical representation of platelets was  pecu-
iar,  due to the characteristic oscillation between visits 2 and
,  and represented a normalized peak from the visit 5, not cor-
oborated  by any relevant clinical alteration. With respect to
his characteristic behavior, we found no comparative analy-
es  with other arthroplasty studies.
The assessment of risk factors for transfusion is of utmost
mportance, since it presupposes an analysis of each individ-
al  that, possibly, be a predictor of normal variation of the
ematimetric curve. Consistent with the literature, this study
uggests  that the risk factors are synergistic and cumulative.27
hat is, the increase in the number of comorbidities of patients
ould  probably be the variable with the greatest impact on the
ndividual’s  propensity to use blood products.27
Risk factors are invariably discussed per se. Preoperatory
emoglobin (Hb),27,28 < 12 g/dL is a predictor that inﬂuenced
he Aderinto and Brenke,18 series in up to 70% of transfused
atients. In our analysis, we did not give much  consider-
tion to this important predictor of risk, because the blood
ransfusions occurred in equal proportions in patients with
b  < 12 g/dL (36.4%) versus Hb > 12 g/dL (34.3%). It is notewor-
hy  that, at randomization, anemic patients (Hb < 11 g/dL)
ere  excluded. Many  of these patients mentioned in Aderinto
nd  Brenkel series,8 Salido et al.28 and Pola et al.27 showed
emoglobin values below 11 g/dL, implying that preoperative
nemia is the decisive factor in the risk of transfusion.
The value of 12 g/dL would be a safety number for perform-
ng  arthroplasties with less risk of use of blood products.28
ther risk factors already mentioned in the literature were
ot  correlated with the results of the present study, includ-
ng  advanced age, which is associated with 43% of anemia
f  chronic disease,4 females,4,6 comorbidities (e.g., diabetes
ellitus and systemic arterial hypertension), low body mass
ndex  – lean patients (risk near 40% in patients < 70 kg),
hort  stature, type of anesthesia and surgical technique.8,27 4;4 9(1):44–50  49
Parker et al.29 state that post-operative anemia should not
be  tolerated in elderly patients’ recovery, giving priority to
aggressive  transfusion conducts (in association with a higher
rate  of falls, cognitive impairment, cardiovascular risk, and
decreased  quality of life). Some peculiar characteristics are
related  to male patients who lose more  blood in prosthetic pro-
cedures. Women, however, tolerate less blood loss and have a
higher risk of transfusion.27 The use of post-operative closed
suction,29 presents further evidence of transfusion risk in elec-
tive  arthroplasties, as well as demonstrating little beneﬁt in
controlling  infections and hematomata.29 Until now, no study
discussed  alcoholism and smoking as possible risk factors, as
well as ethnicity. In our study, black people had a lower ten-
dency  to blood transfusion. Bell et al.6 associated prophylaxis
for  deep venous thrombosis (DVT) with unfractionated hep-
arin  to increased chances of transfusion, but with no reason
established.
Interestingly, Carson et al.24 and Pola et al.27 were  remark-
able in the establishment of transfusional conducts in patients
undergoing  orthopedic procedures.23,30 These authors deter-
mined  that, initially, the use of blood products should
precede objective parameters (laboratory indices), but that
the  subjective parameters (clinical and comorbidities’ analy-
sis)  rationalize the practice of transfusion. With this objective,
they  observed a decrease in the percentage and amount of
transfusion  without additional risks of mortality and myocar-
dial  infarct.30 We  support this transfusion practice and,
through our study, we conﬁrm too the possibility of improv-
ing  the use of blood products. Other optional methods to
avoid  transfusion measures with signiﬁcance level still have
high  costs (such as recombinant erythropoietin,4), or gaps
regarding  their practicity.4,11,13,15
Conclusions
The rate of blood transfusion among patients treated with hip
arthroplasty  was  34.6%.
There is a pattern of behavior of the post-operatory
hemoglobin and hematocrit curve that follows a parabola with
normal  distribution. However, the platelet curve follows an
oscillatory  path of the normal curve.
The hematimetric curve has limited reliability when used
as  the sole and absolute parameter.
The clinical and functional analysis of the patient and of its
comorbidities constitutes the best parameter to inﬂuence the
decision  to use blood products, in association with laboratory
evaluation.
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